Arcus Biosciences, Inc. - RCUS STOCK NEWS

Arcus Biosciences (NYSE:RCUS) and Taiho Pharmaceutical announced the exercise of Taiho's option for the anti-TIGIT antibodies, domvanalimab and AB308, in Japan and parts of Asia. This follows a prior agreement from September 2017. Taiho will make an upfront payment and additional milestone payments. Domvanalimab is in Phase 2 and Phase 3 trials for non-small cell lung cancer, while AB308 is in a Phase 1b trial for various malignancies. The collaboration aims to enhance the development and commercialization of these therapies.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of options to purchase 76,000 shares to ten new employees at an exercise price of $48.47, reflecting the closing price on November 23, 2021. This action is part of the 2020 Inducement Plan approved in January 2020. The company focuses on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies targeting vital biological pathways. For further details, visit www.arcusbio.com.

Arcus Biosciences, Inc. (NYSE: RCUS) announced participation in a fireside chat at the Evercore ISI HealthCONx 2021 Conference on December 1, 2021, at 4:20 p.m. ET. A live audio webcast will be accessible through the company's website, with a replay available for two weeks post-event. Founded in 2015, Arcus is focused on developing novel therapies for cancer, with six investigational medicines in clinical studies targeting various pathways, including TIGIT and PD-1. For more details on their programs, visit www.arcusbio.com.

Gilead Sciences has exercised options for three clinical-stage programs from Arcus Biosciences, including anti-TIGIT agents domvanalimab and AB308, as well as etrumadenant and quemliclustat. This move involves $725 million in option payments to Arcus. The companies are set to co-develop these candidates, share global costs, and explore innovative treatment combinations. Antitrust clearance is required, with expected closure by year-end.

Gilead Sciences has exercised options for three clinical-stage programs from Arcus Biosciences, including domvanalimab, AB308, etrumadenant, and quemliclustat. The agreement, subject to antitrust clearance, results in Arcus receiving $725 million in option payments. The collaboration aims to accelerate the clinical development of these programs, which target hard-to-treat cancers like lung and pancreatic cancer. Notably, Gilead will pursue novel treatment combinations, enhancing its oncology portfolio.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of stock options to a new employee, totaling 28,000 shares at a price of $34.74 each, reflecting the closing price as of November 8, 2021. This issuance is part of the company's 2020 Inducement Plan, approved by the Board of Directors in January 2020. The company focuses on developing cancer therapies, with six investigational drugs currently in clinical studies targeting well-characterized biology and pathways.

Arcus Biosciences (RCUS) reported Q3 2021 results, showing a net loss of $78 million, a significant decline from net income of $1.8 million in Q3 2020. Collaboration revenues dropped to $9.5 million vs. $64.5 million year-over-year. Cash and investments rose to $743 million, providing funding through at least 2023. Gilead is reviewing an opt-in for Arcus's anti-TIGIT program, potentially yielding a $275 million payment. The ARC-7 study showed superior efficacy for domvanalimab combinations in non-small cell lung cancer. However, R&D expenses surged, raising concerns about financial sustainability.

Arcus Biosciences, Inc. (NYSE:RCUS) announced it will report its financial results and corporate update for Q3 2021 on November 8, 2021, after market close. The company focuses on developing innovative molecules and combination therapies for cancer treatment, working on five investigational medicines targeting pathways like TIGIT and PD-1. Founded in 2015, Arcus aims to expedite the development of first or best-in-class cancer therapies through collaboration with industry partners, patients, and physicians.

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company, announced the grant of stock options to six new employees. These options total 48,800 shares at an exercise price of $34.38, based on the closing price from October 25, 2021. The stock options were issued under the 2020 Inducement Plan approved by the Board of Directors in January 2020. The company continues to develop innovative cancer therapies, with five molecules currently in clinical development targeting significant unmet needs in oncology.